Seminars in Nuclear Medicine
Volume 35, Issue 3 , Pages 165-175 , July 2005

Initial Staging of Lymphoma With Positron Emission Tomography and Computed Tomography

  • Rodney J. Hicks, MBBS (Hons), MD (FRACP)

      Affiliations

    • Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
    • Department of Medicine, St. Vincent’s Medical School, University of Melbourne, Melbourne, Australia.
    • Corresponding Author InformationAddress reprint requests to Rodney J. Hicks, MBBS (Hons), MD, FRACP, Centre for Molecular Imaging, The Peter MacCallum Cancer Centre, 12 Cathedral Place, East Melbourne, VIC 3002, Australia.
    • ,
  • Michael P. Mac Manus, MD (FRCR)

      Affiliations

    • Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
    • ,
  • John F. Seymour, MBBS (FRACP)

      Affiliations

    • Division of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.

References 

  1. Cheson BD , Horning SJ , Coiffier B , et al.  NCI Sponsored International Working Group   Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas . J Clin Oncol . 1999;17:1244–1253
  2. Newman JS , Francis IR , Kaminski MS , et al.   Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose (Correlation with CT) . Radiology . 1994;190:111–116
  3. Schaefer NG , Hany TF , Taverna C , et al.   Non-Hodgkin lymphoma and Hodgkin disease (Coregistered FDG PET and CT at staging and restaging—do we need contrast-enhanced CT?) . Radiology . 2004;232:823–829
  4. Harris NL , Jaffe ES , Diebold J , et al.   World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues; report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997 . J Clin Oncol . 1999;17:3835–3849
  5. Hasenclever D , Diehl V . A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease . N Engl J Med . 1998;339:1506–1514
  6. Shipp MA , Harrington DR , Anderson JR , et al.   A predictive model for aggressive Non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project . N Engl J Med . 1993;329:987–994
  7. Armitage JO . Long-term toxicity of the treatment of Hodgkin’s disease . Ann Oncol . 1998;9:S133–S136
  8. Specht L , Gray RG , Clarke MJ , et al.  International Hodgkin’s Disease Collaborative Group   Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin’s disease (A meta-analysis of 23 randomized trials involving 3,888 patients) . J Clin Oncol . 1998;16:830–843
  9. Duhmke E , Diehl V , Loeffler M , et al.   Randomized trial with early-stage Hodgkin’s disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone . Int J Radiat Oncol Biol Phys . 1996;36:305–310
  10. Diehl V , Sextro M , Franklin J , et al.   Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease (Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease) . J Clin Oncol . 1999;17:776–783
  11. Campbell JK , Matthews JP , Seymour JF , et al.   Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma . Ann Oncol . 2003;14:273–276
  12. Yasumoto M , Nonomura Y , Yoshimura R , et al.   MR detection of iliac bone marrow involvement by malignant lymphoma with various MR sequences including diffusion-weighted echo-planar imaging . Skeletal Radiol . 2002;31:263–269
  13. Mac Manus MP , Hoppe RT . Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University . J Clin Oncol . 1996;14:1282–1290
  14. Seymour JF , Pro B , Fuller LM , et al.   Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin’s lymphoma . J Clin Oncol . 2003;21:2115–2122
  15. Seymour JF . New treatment approaches to indolent non-Hodgkin’s lymphoma . Semin Oncol . 2004;31(Suppl 2):27–32
  16. Forstpointner R , Dreyling M , Repp R , et al.   The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas (Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group) . Blood . 2004;104:3064–3071
  17. Coiffier B , LePage E , Briere J , et al.   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma . N Eng J Med . 2002;346:235–242
  18. Young CS , Young BL , Smith SM . Staging Hodgkin’s disease with 18-FDG PET (Comparison with CT and surgery) . Clin Pos Imaging . 1998;1:161–164
  19. Moog F , Bangerter M , Diederichs CG , et al.   Lymphoma (Role of whole-body 2-deoxy-2-[F-18]-fluoro-D-glucose (FDG) PET in nodal staging) . Radiology . 1997;203:795–800
  20. Bangerter M , Moog F , Buchmann I , et al.   Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease . Ann Oncol . 1998;9:1117–1122
  21. Moog F , Bangerter M , Diederichs CC , et al.   Extranodal malignant melanoma (Detection with FDG PET versus CT) . Radiology . 1998;206:475–481
  22. Bangerter M , Kotzerke J , Griesshammer M , et al.   Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest . Acta Oncol . 1999;38:799–804
  23. Kostakoglu L , Leonard JP , Kuji I , et al.   Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma . Cancer . 2002;94:879–888
  24. Tatsumi M , Kitayama H , Sugahara H , et al.   Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin’s lymphoma . J Nucl Med . 2001;42:601–608
  25. Stumpe KD , Dazzi H , Schaffner A , et al.   Infection imaging using whole-body FDG-PET . Eur J Nucl Med . 2000;27:822–832
  26. Hueltenschmidt B , Sautter-Bihl ML , Lang O , et al.   Whole body positron emission tomography in the treatment of Hodgkin disease . Cancer . 2001;91:302–310
  27. Buchmann I , Reinhardt M , Elsner K , et al.   2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial . Cancer . 2001;91:889–899
  28. Beyer T , Townsend DW , Brun T , et al.   A combined PET/CT scanner for clinical oncology . J Nucl Med . 2000;41:1369–1379
  29. Jerusalem G , Beguin Y , Najjar F , et al.   Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL) . Ann Oncol . 2001;12:825–830
  30. Hoffmann M , Kletter K , Diemling M , et al.   Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type . Ann Oncol . 1999;10:1185–1189
  31. Front D , Barshalom R , Epelbaum R , et al.   Early detection of lymphoma recurrence with gallium-67 scintigraphy . J Nucl Med . 1993;34:2101–2104
  32. Paul R . Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma . J Nucl Med . 1987;28:288–292
  33. Wirth A , Seymour JF , Hicks RJ , et al.   Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma . Am J Med . 2002;112:262–268
  34. Carr R , Barrington SF , Madan B , et al.   Detection of lymphoma in bone marrow by whole-body positron emission tomography . Blood . 1998;91:3340–3346
  35. Moog F , Bangerter M , Kotzerke J , et al.   18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow . J Clin Oncol . 1998;16:603–609
  36. Okada J , Yoshikawa K , Itami M , et al.   Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma (A comparison with proliferative activity) . J Nucl Med . 1992;33:325–329
  37. Lapela M , Leskinen S , Minn HR , et al.   Increased glucose metabolism in untreated non-Hodgkin’s lymphoma (A study with positron emission tomography and fluorine-18-fluorodeoxyglucose) . Blood . 1995;86:3522–3527
  38. Goldberg MA , Lee MJ , Fischman AJ , et al.   Fluorodeoxyglucose PET of abdominal and pelvic neoplasms (Potential role in oncologic imaging) . Radiographics . 1993;13:1047–1062
  39. Rodriguez M , Rehn S , Ahlstrom H , et al.   Predicting malignancy grade with PET in non-Hodgkin’s lymphoma . J Nucl Med . 1995;36:1790–1796
  40. Okada J , Oonishi H , Yoshikawa K , et al.   FDG-PET for predicting the prognosis of malignant lymphoma . Ann Nucl Med . 1994;8:187–191
  41. Valk PE , Pounds TR , Tesar RD , et al.   Cost-effectiveness of PET imaging in clinical oncology . Nucl Med Biol . 1996;23:737–743
  42. Schoder H , Meta J , Yap C , et al.   Effect of whole-body 18F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma . J Nucl Med . 2001;42:1139–1143
  43. Montravers F , McNamara D , Landman-Parker J , et al.   18FDG in childhood lymphoma (Clinical utility and impact on management) . Eur J Nucl Med . 2002;29:155–1165
  44. Blum RH , Seymour JF , Wirth A , et al.   Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin’s lymphoma . Clin Lymphoma . 2003;4:43–49
  45. Shields AF , Grierson HR , Dohmen BM , et al.   Imaging proliferation in vivo with [F-18]FLT and positron emission tomography . Nat Med . 1998;4:1334–1336
  46. Allen-Auerbach M , Quon A , Weber WA , et al.   Comparison between 2-deoxy-2-[18F]fluoro-D-Glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma . Mol Imaging Biol . 2004;6:411–416

PII: S0001-2998(05)00013-9

doi: 10.1053/j.semnuclmed.2005.02.003

Seminars in Nuclear Medicine
Volume 35, Issue 3 , Pages 165-175 , July 2005

Article Tools

* Image Usage & Resolution